ICU Antipsychotic Exposure Linked to Fewer Catatonia-Free Days

The Hidden Cost of Dopamine Blockade in Critical Care

Catatonia is increasingly recognized as an independent, severe neuropsychiatric syndrome that complicates a wide range of medical and psychiatric conditions [1]. While clinicians often rely on antipsychotic medications to manage acute agitation and delirium in hospital settings, these dopamine-blocking agents carry well-documented risks, including neuroleptic malignant syndrome and antipsychotic-induced catatonia [2, 3]. The exact pathophysiological mechanisms driving catatonia remain complex, but evidence points toward dopamine receptor blockade as a significant precipitating factor [2, 4]. Despite these known risks, the direct impact of routine antipsychotic administration on catatonia development in the intensive care unit has remained poorly quantified. A prospective cohort study of 270 critically ill patients now offers specific clinical data, demonstrating that antipsychotic exposure is associated with a 74% reduction in the odds of experiencing more catatonia-free days (the number of days a patient remains alive and without catatonic symptoms) within the first five days of admission, with higher cumulative doses reducing these odds by 97% [5].

Defining the ICU Cohort and Catatonia Metrics

To investigate the relationship between dopamine blockade and catatonia, researchers utilized data from the Delirium and Catatonia Prospective Cohort Investigation. The study was conducted across the medical, surgical, and trauma intensive care units of a single academic medical center. The final cohort included 270 critically ill adult patients who required either mechanical ventilation or vasopressors to maintain life support. The enrolled patients had a median age of 54.5 years, with an interquartile range of 36.7 to 67.2 years. To ensure that pre-existing conditions did not confound the results, the investigators strictly excluded any patients who presented with a major neurocognitive disorder, a severe psychiatric disorder, or active catatonia at baseline.

The primary exposure of interest was antipsychotic administration, specifically evaluating both any use and the cumulative dosage administered during the first 5 and 14 days from enrollment. To measure the primary outcome, the researchers tracked catatonia-free days, defined as the total number of days a patient remained alive and completely free from catatonia. Clinical assessments for the syndrome were rigorously conducted using the Bush-Francis Catatonia Rating Scale, a standardized clinical tool used to identify and grade the severity of catatonic signs. These scores were subsequently mapped to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria to confirm the diagnosis. To analyze the data, the research team applied adjusted proportional odds logistic regression (a statistical method used to predict the probability of achieving a higher number of healthy days) to estimate the odds ratio of the outcome events. This approach allowed them to quantify the exact impact of antipsychotic exposure on the number of days patients survived without developing catatonic symptoms.

Quantifying the Risk of Antipsychotic Exposure

When analyzing the clinical outcomes of the cohort, the researchers observed a high incidence of the syndrome among those receiving dopamine-blocking agents. Specifically, out of 102 patients exposed to antipsychotic medication, a total of 27 (26%) experienced catatonia. This absolute rate highlights a substantial clinical risk for critically ill patients managed with these common pharmacological interventions, suggesting that routine chemical restraints may inadvertently complicate a patient's neurological recovery.

To rigorously quantify this risk, the investigators compared the exposed group to patients who were never exposed to antipsychotics across two distinct timeframes. In the 5-day model, patients exposed to antipsychotics had a 74% reduction in the odds of more catatonia-free days compared with those never exposed (odds ratio, 0.2568; 95% confidence interval, 0.1580 to 0.4173). The negative impact on patient outcomes persisted over a longer observation period. In the 14-day model, patients exposed to antipsychotics had a 51% reduction in the odds of more catatonia-free days compared with those never exposed (odds ratio, 0.4939; 95% confidence interval, 0.3857 to 0.6325). For practicing intensivists, these data provide concrete evidence that administering antipsychotics directly correlates with fewer days alive and free of catatonic symptoms, prompting a need to carefully reevaluate agitation management protocols.

Dose-Dependent Effects and Clinical Implications

Beyond the binary risk of exposure, the researchers identified a severe dose-response relationship among the treated cohort. In the 5-day model, patients exposed to higher cumulative dosages of antipsychotics had a 97% reduction in the odds of more catatonia-free days compared with those exposed to lower dosages (odds ratio, 0.0281; 95% confidence interval, 0.0142 to 0.0556). This profound negative effect on patient outcomes remained consistent over a longer observation period. In the 14-day model, patients exposed to higher dosages also experienced a 97% reduction in the odds of more catatonia-free days compared with those exposed to lower dosages (odds ratio, 0.0335; 95% confidence interval, 0.0166 to 0.0673).

These dose-dependent outcomes provide critical pathophysiological insights, building upon existing evidence that dopamine blockade is a primary biologic mechanism underlying catatonia. Because antipsychotics function primarily by antagonizing dopamine receptors, administering higher cumulative doses directly exacerbates the risk of precipitating this severe neuropsychiatric syndrome. Consequently, these findings should influence how intensivists approach the use of antipsychotic medications in the intensive care unit. Clinicians managing acute agitation or delirium in critically ill patients must weigh the immediate behavioral control offered by these drugs against the substantial, dose-related risk of inducing catatonia and reducing overall survival days free of the syndrome.

References

1. Francis A, Mormando C. Catatonia and its varieties: an update. World Psychiatry. 2023. doi:10.1002/wps.21119

2. Virolle J, Redon M, Montastruc F, et al. What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review.. Schizophrenia research. 2023. doi:10.1016/j.schres.2023.08.003

3. Rogers J, Oldham M, Fricchione GL, et al. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology. 2023. doi:10.1177/02698811231158232

4. Sarmiento B, Gunther M, Cohen-Oram A, Jiang S. Bromocriptine for Residual Catatonia Following Neuroleptic Malignant Syndrome: Illustrative Case Report and Systematic Review.. Journal of the Academy of Consultation-Liaison Psychiatry. 2025. doi:10.1016/j.jaclp.2024.12.003

5. Mina GN, McGonigle T, Liu J, et al. Exposure to Antipsychotic Medication Is Associated With Less Days Alive and Free From Catatonia in Critically Ill Patients.. Critical care medicine. 2026. doi:10.1097/CCM.0000000000007077